NCT05855941 Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)
| NCT ID | NCT05855941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Västerbotten |
| Condition | Cervix Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-05-23 |
| Primary Completion | 2032-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2023-05-23 with a primary completion date of 2032-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are: * Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue? Participants will * Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.
Eligibility Criteria
Inclusion Criteria: * Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer. * Known clinical FIGO stage. * \>18 years old. * No other known current or previous malignancy within the last 10 years. Exclusion Criteria: * Imaging findings suggestive of other primary malignancy. * Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or "cancer abdominis". * MRI incompatible devices or patient unable to undergo MRI.
Contact & Investigator
Sara Strandberg, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Radiation Sciences, Umea University/Radiology, Umea University Hospital
Frequently Asked Questions
Who can join the NCT05855941 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervix Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05855941 currently recruiting?
Yes, NCT05855941 is actively recruiting participants. Contact the research team at erika.figaro@regionvasterbotten.se for enrollment information.
Where is the NCT05855941 trial being conducted?
This trial is being conducted at Umeå, Sweden.
Who is sponsoring the NCT05855941 clinical trial?
NCT05855941 is sponsored by Region Västerbotten. The principal investigator is Sara Strandberg, MD, PhD at Department of Radiation Sciences, Umea University/Radiology, Umea University Hospital. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.